The six-gene panel mutation assay was designed to detect the most common mutations found in EGFR, KRAS, PIK3CA, NRAS, BRAF, and AKT1. Activating mutations in these genes cause aberrant cell signaling and are found in various types of cancer; their encoded proteins are therefore targets for therapeutic inhibition. The gene discussed is EGFR; the disease is cancer.